Digital Use and Factors Linked to Staying on Semaglutide and Losing Weight in Severe Obesity Over 48 Weeks

Only 32% to 50% of patients persist with glucagon-like peptide-1 receptor agonists at 12 months.

• Fewer than 15% of patients achieve the 2.4 mg/week target dose of these medications.
• Real-world persistence with antiobesity pharmacotherapy is described as suboptimal.
• Digital platforms may have the potential to support patient engagement.
• The role of digital platforms in enhancing persistence with this treatment is not well understood.

Simplified